Next Generation Storage Devices Market is expected to reach $141 billion by 2022. The cloud-based storage segment is expected to dominate the global market. North America accounted for 35% market share in 2014, while the European market is expected to witness significant growth rate during the forecast period.
Get Full Summary of this report study @ https://www.alliedmarketresearch.com/next-generation-storage-devices-market
Next generation storage technology is a high-tech technology that provides improved data storage and management for various industries, such as BFSI, retail, IT & telecommunication, government, healthcare, manufacturing, and others. The market growth is driven by technological advancements, increased smartphone penetration, a rise in online transactions, lower cost of cloud computing platforms, and high internet penetration worldwide.
The cloud-based storage segment dominated the global next-generation storage devices industry in 2014, with around 38% share. However, the solid-state storage technology is gaining momentum, owing to its various advantages such as high performance and low noise creation over conventional data storage devices. Cloud-based storage is expected to grow at the highest CAGR of 18.7% during the forecast period, followed by solid-state storage.
The BFSI and IT & telecommunication segments collectively accounted for around 35% share of the total market revenue in 2014, while the government segment is anticipated to grow at the highest CAGR of 18.1%. The BFSI next-generation storage devices market is expected to grow at the second highest CAGR of 17.8%, owing to the surge in digitization, increase in online banking activities, and rise in adoption of private and hybrid cloud in the sector.
Get PDF Brochure of this report study @ https://www.alliedmarketresearch.com/request-sample/2114
Key Findings of the Next Generation Storage Devices Market:
• The cloud-based storage segment dominated the overall next-generation storage devices market, in terms of revenue, and is projected to grow at a CAGR of 18.7% during the forecast period.
• The cloud storage system segment dominated the global next-generation storage devices market in 2014, and is anticipated to grow at the highest CAGR.
• The software-defined storage segment is expected to grow at the second highest growth rate of 17.7%.
• IT & telecommunication generated the highest revenue in 2014, while the government sector is estimated to grow at the highest growth rate of 18.1%.
• In 2014, North America was the dominant region, while Europe is projected to grow at the highest CAGR, with rest of Europe market being the major contributor.
Key players operating in the next generation storage devices market include Dell, Inc., HPE Company, Hitachi Ltd., IBM Corporation, NetApp, Inc., Nutanix, Inc., Oracle StorageTek, Pure Storage, Inc., Tintri, Inc., and Toshiba Corp.
Crop micronutrients are essential elements for plant growth and play an important role in balanced crop nutrition. The lack of micronutrients can lead to various diseases in plants such as chlorosis, yellowing of leaves, gummosis, and others that can reduce the quality and quantity of plants. Crop micronutrients maintain the nutrient level in crops & soil to enhance the productivity and growth of crops. These nutrients find extensive applications in agribusiness, thereby driving the crop micronutrients industry.
The global crop micronutrients market is projected to reach $11,532.36 million by 2025, registering a CAGR of 8.3% from 2018 to 2025. In 2017, the soil application segment accounted for more than 50% share of the global crop micronutrients market in terms of value.
Get PDF Brochure of this report study @ https://www.alliedmarketresearch.com/request-sample/3568
Micro-nutrients act as enzyme co-factors and building blocks that enable plants to build complete proteins and compounds. They also aid in the development of large, strong roots, and boost immunity of the plant. Growth in awareness about benefits of micronutrients among farmers & growers, increase in demand for healthy & nutritious food, surge in demand for biofuels fuel the global crop micronutrients market.
In terms of value, Asia-Pacific and LAMEA collectively contributed xx share in the global crop micronutrients market in 2017. The key players operating in the crop micronutrients market are Akzo Nobel N.V., Aries Agro Ltd., Baicor, L.C., BASF SE., Compass Minerals International, Inc., DowDuPont Inc., The Mosaic Company, Nutrien Ltd., Western Nutrients Corporation, and Yara International.
Hadoop-as-a-Service (HaaS) Market report, published by Allied Market Research, forecasts that the global market is expected to garner $16.1 Billion Globally by 2020, registering a CAGR of 70.8% during the forecast period 2014 to 2020. In the current business scenario, HaaS market is majorly constricted to North America. Amazon Elastic Map Reduce was the most prominent service, accounting to nearly 85% of the global market revenue in 2013.
Get PDF Brochure of this Insight @ https://www.alliedmarketresearch.com/request-sample/489
HaaS made a grand ingress in the big data analytic market in last couple of years. The advent of this novel technology is highly appreciated among the data scientists and among the SMEs. The market has doubled itself in 2013 (from 2012) and is now gaining prominence among conventional Hadoop users. Noteworthy, Hadoop-as-a-service is expected to give a tough competition to on-premises-Hadoop in the coming years. The outburst of HaaS is anticipated to overcast the growth of the on-premises Hadoop market through 2020. With an optimistic view, AMR analysts further predict that the market would witness a strong bullish run during 2020 – 2025.
Hadoop-as-a-Service market is evolving and current users include SaaS providers, social media companies, and gaming companies. The technology is yet to enter into the mainstream commercial market. However, it is expected to witness a tremendous growth in the next 7 years, expanding its horizon into the end user industries of conventional hadoop.
For purchase enquiry, visit @ https://www.alliedmarketresearch.com/purchase-enquiry/489
“Hadoop in the Cloud” (HaaS/HDaaS) holds numerous benefits over conventional Hadoop. Low upfront cost (for both run it yourself and pure play HaaS) and non-technical interface (in case of pure play) are the crucial dynamics propelling the market. Many providers are coming up with graphic and excel based interfaces, which makes Hadoop operations easier than ever. HaaS adds flow to business operations as providers take sole responsibility of running and managing Hadoop jobs. SMEs, social media firms, SaaS providers. Gaming companies are largely contributing to HaaS revenue, and the growing demand for HaaS by these business entities is further fueling the market.
The evolution of smaller pure play/managed HaaS players, despite the presence of giants such as IBM and Microsoft, has grabbed the attention as these smaller players are making strong inroads to the market. However, AWS has been a common storage platform for most of these HaaS providers. Cloudera, one of the leaders in Hadoop, offers CDH3 as a HaaS offering. Microsoft Corporation, IBM Corp., Amazon Web Services, Cloudera, Inc., Datameer, Inc., Hortonworks, MAPR Technologies, Emc Corp., Mortar Data Inc. and Altiscale are among key market participants analyzed in this report.
In pursuit of more targeted therapies and clinically effective drugs, pharmaceutical companies are increasing their research and development activities in biologics. Although a majority of this work is focused on monoclonal antibodies (mAbs) and recombinant proteins, progress is being made in specialized drugs. Antibody drug conjugates (ADCs) are a new class of drugs that is gaining attention from both large and small pharmaceutical companies as they offer promise in cancer therapeutics. They consist of an mAb – an antibody that is specific to the target associated antigen, a cytotoxic drug – designed to kill target cancer cells, and a linker – that attaches the cytotoxic agent to the antibody. Thus, antibody drug conjugates combine the targeting ability of monoclonal antibody and the target specific cell killing ability of cytotoxic drugs.
The market for antibody drug conjugates is witnessing a fast growth, which is supported by the advancement in medical technology, the rise in the occurrence of cancer cases worldwide, growing ageing population, and the growing obese population. Furthermore, the increased research activities on antibody therapies, advanced drug discoveries and oncology diseases as well as the growing collaboration between research institutes are propelling the growth of the industry. Nonetheless, the high cost of the procedures and the lack of fund pose a threat to the growth of the ADC market. According to a report published by Allied Market Research, the antibody drug conjugates market is expected to reach $3,198 million by 2023, registering a CAGR of 12.9% from 2017 to 2023.
Companies within the space are coming up with superior technologies to develop more effective and efficient antibody drug conjugates. For instance, ADC Therapeutics, a developer of proprietary PBD-based antibody drug conjugates, recently announced that it would deliver its presentations regarding strong preclinical data for its two new investigational programs ADCT-601 targeting AXL and ADCT-701 targeting DLK-1 at the American Association for Cancer Research (AACR) Annual Meeting. Daiichi Sankyo, a global pharmaceutical company announced that its HER2-targeting antibody drug conjugate (ADC) received SAKIGAKE Designation for the treatment of gastric cancer by the Japan Ministry of Health, Labor and Welfare (MHLW). Synaffix, a Netherlands-based biotech company announced the launch of a new platform of highly potent cytotoxic ADC payloads that integrates into its existing ADC platform.
ADC Therapeutics to Present Two Novel ADCs
In April 2018, ADC Therapeutics announced its presentation regarding strong preclinical data for its two new investigational programs ADCT-601 targeting AXL and ADCT-701 targeting DLK-1 at the American Association for Cancer Research (AACR) Annual Meeting which takes place from April 14-18, 2018 in Chicago, USA. Dr. Jay Feingold, Chief Medical Officer and Senior Vice President of Clinical Development at ADCT said, “Our two new investigational programs show compelling efficacy and safety in preclinical studies. These results provide an important step to advance ADCT-601 and ADCT-701 into the clinic and enlarge our pipeline of PBD-based ADCs in multiple ongoing clinical trials for the treatment of both solid and hematological cancers.” Highlights of the data to be presented are available on the AACR conference website at http://www.aacr.org
Daiichi Sankyo’s HER2-Targeting Antibody Drug Conjugate Receives SAKIGAKE Designation for Gastric Cancer
In March 2018, Daiichi Sankyo announced that DS-8201, an HER2-targeting antibody drug conjugate (ADC) received SAKIGAKE Designation for the treatment of HER2-positive advanced gastric or gastroesophageal junction cancer by the Japan Ministry of Health, Labor, and Welfare (MHLW). The company said that it intends to work closely with the Japan MHLW under the terms of the SAKIGAKE program to speed up the development of DS-8201 since Japan has one of the highest cases of gastric cancer worldwide. The SAKIGAKE Designation system fosters R&D in Japan, propelling early practical application for novel pharmaceutical products, medical devices, and regenerative medicines. As a designated medicine under the system, DS-8201 has prioritized consultation, a dedicated review system to support the development and review process, and a reduced review time.
Synaffix Launches toxSYN, a New Platform of ADC Payloads
Synaffix BV, a biotechnology company announced thgrowinge launch of a new platform of cytotoxic ADC payloads that integrates into its current ADC platform. With the launch, the company becomes a provider of technologies needed to quickly translate antibodies into proprietary ADC products. The new toxSYN platform comprises four highly potent payloads offering multiple mechanisms of action and a way for commercialization when integrated with the components of Synaffix’s GlycoConnect and HydraSpace technologies. Validated clinically with well-known efficacy and safety profiles, the payloads were selected to address the two types of biologies that exist across ADC targets such as rapidly-dividing cancer cells and quiescent cells. “We expect this important expansion of our ADC technology to further advance our internal research and facilitate collaborations with a much broader set of companies,” said Peter van de Sande, CEO of Synaffix. “By providing these four distinct payloads through our new toxSYN platform, we can now enable any company with an existing antibody to rapidly establish a highly-competitive clinical-stage ADC program for its own development pipeline.”
Source: Allied Market Research
The increase in awareness in regards with the benefits of using gene therapy as compared to conventional therapy for the treatment of various diseases and government support to promote gene therapy related research are the major driving factors that are projected to boost the market growth.
Gene-fixing treatments have now cured a number of patients with cancer and rare diseases. Genes are composed of DNA that contains necessary information for making proteins that are vital for the human body to function optimally. Some gene mutations result in these proteins not being made correctly and can lead to genetic disorders. Gene therapy works by repairing, repressing, or replacing dysfunctional genes that cause disease with the aim of reestablishing normal function. Gene therapy is an attractive area for drug development because with the right target and approach, it can address the root cause of a severe disease. For certain disorders where known genetic mutations lead to deficient or non-functional protein production, gene therapy can fix the underlying defect and provide a path to produce the functional protein.
Check out the “Gene Therapy” Research Report and Get the Sample PDF at: https://tinyurl.com/y77mcfae
Gene therapy—the idea of modifying a person’s DNA to treat disease—represents a major shift in medicine. Instead of just treating symptoms like the vast majority of drugs on the market, gene therapy aims to correct the underlying genetic cause of a disease. Doctors and scientists hope these treatments will be a one-shot cure.
Last year, we wrote that 2016 was gene therapy’s most promising year. But 2017 proved to be even bigger. Gene therapy had a hell of a 2017. After decades of promises but failed deliveries, last year saw the field hitting a series of astonishing home runs.
The concept of gene therapy is elegant: like computer bugs, faulty letters in the human genome can be edited and replaced with healthy ones.
But despite early enthusiasm, the field has suffered one setback after another. At the turn of the century, the death of an 18-year-old patient with inherited liver disease after an experimental gene therapy treatment put the entire field into a deep freeze.
But no more. Last year marked the birth of gene therapy 2.0, in which the experimental dream finally became a clinical reality. Here’s how the tech grew into its explosive potential—and a sneak peek at what’s on the horizon for 2018.
The global gene therapy market was valued at $584 million in 2016, and is estimated to reach $4,402 million by 2023, registering a CAGR of 33.3% from 2017 to 2023. Due to the high success rate during the preclinical and clinical trial, gene therapy is gaining popularity. There are many techniques used for gene therapy, for example, a procedure where the mutated gene is being replaced with a healthy gene or inactivation of gene whose function is abnormal.
Tumor suppressor and suicide gene therapy are expected to be a lucrative segment for the market players as they are among the fastest growing segment in the gene therapy market. The therapy involves the introduction of new genes into the tumor cells that help destroy the tumor cells without affecting the neighboring healthy cells.
How Does Gene Therapy Work?
Gene therapy is designed to introduce genetic material into cells to compensate for abnormal genes or to make a beneficial protein. If a mutated gene causes a necessary protein to be faulty or missing, gene therapy may be able to introduce a normal copy of the gene to restore the function of the protein.
A quality that is embedded straightforwardly into a cell more often than not does not work. Rather, a bearer called a vector is hereditarily built to convey the quality. Certain infections are frequently utilized as vectors since they can convey the new quality by contaminating the cell. The infections are adjusted so they can’t cause sickness when utilized as a part of individuals. A few kinds of infection, for example, retroviruses, incorporate their hereditary material (counting the new quality) into a chromosome in the human cell. Different infections, for example, adenoviruses, bring their DNA into the core of the phone, however the DNA isn’t incorporated into a chromosome.
The vector can be infused or given intravenously (by IV) specifically into a particular tissue in the body, where it is taken up by singular cells. On the other hand, an example of the patient’s cells can be evacuated and presented to the vector in a research facility setting. The cells containing the vector are then come back to the patient. On the off chance that the treatment is fruitful, the new quality conveyed by the vector will make a working protein.
Specialists must defeat numerous specialized difficulties previously quality treatment will be a reasonable way to deal with treating ailment. For instance, researchers must discover better approaches to convey qualities and target them to specific cells. They should likewise guarantee that new qualities are absolutely controlled by the body.
The key players operating in the global gene therapy market include Novartis, Kite Pharma, Inc., GlaxoSmithKline PLC, Spark Therapeutics Inc., Bluebird bio Inc., Genethon, Transgene SA, Applied Genetic Technologies Corporation, Oxford BioMedica, and NewLink Genetics Corp.
Other prominent players in the value chain include Amgen, Epeius Biotechnologies, Abeona Therapeutics, Sanofi, UniQure, Juno Therapeutics, Adaptimmune, Celgene, and Advantagene.
Do purchase Inquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/2841
Polymerase Chain Reaction Technologies Market Anticipated to Reach $10,776 Million, Globally, by 2023
According to a new report published by Allied Market Research, titled, Polymerase Chain Reaction Market by Technology, Products, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023,” the polymerase chain reaction market accounted for $7,027 million in 2016, and is estimated to reach $10,776 million by 2023, registering a CAGR of 6.2% from 2017 to 2023. North America is the highest contributor in the polymerase chain reaction market; however, Asia-Pacific is expected to witness the highest growth rate.
Access Full Summary at: https://www.alliedmarketresearch.com/polymerase-chain-reaction-market
PCR techniques have the most potential features such as absolute detection and quantification of genetic materials such as DNA and RNA that are increasingly being used in life sciences research and molecular diagnostics. The device can be used quantify and analyze rare alleles and point mutations. Advanced PCR systems are being developed with enhanced capabilities such as broad menu of tests, higher sensitivity, and specificity. Other major advances related with the PCR are shorter PCR cycling time, higher productivity, and automated workflow.
The advancement in the technology of qPCR and dPCR leading to automation, improved accuracy, and enhanced sensitivity majorly drive the market growth. These products provide high level of efficiency and productivity in research and drug discovery and reduce the time required for the novel drug development. In addition, there is increased demand for polymerase chain reaction technologies owing to increase in number of hospitals and research centers. Furthermore, the increase in number of patients suffering from infectious diseases and rise in funding in gene therapy and human genome projects will also help to fuel the growth of the global polymerase chain reaction technologies market. Moreover, there is growth in demand for polymerase chain reaction technologies in the field of life science, clinical diagnostics, and others, which would further drive the market. However, growth of non-validated home brew test and unstable reimbursement policies are projected to hinder the growth of global polymerase chain reaction technologies market.
The real-time PCR segment is the major contributor towards the global PCR market in 2016, due to several factors including increase in use of qPCR in research and medical diagnostics, technological advancements, growing use of robotics for lab automation, and expansion of installation base.
Among the end-users, academic & research institutions occupied the major share of PCR instrument market due to increased test volume of infectious diseases and various types of cancers.
In 2016, North America accounted for maximum contribution to the total revenue generated, owing to the rise in prevalence of infectious diseases and cancer in this region and technological advancement in PCR. However, Asia is projected to grow at the highest CAGR during the forecast period. Opportunities in the Asian market have attracted huge investments by major companies in the area of R&D activities.
Key Findings of the Polymerase Chain Reaction Market:
- Digital PCR segment is projected to grow at the highest rate during the analysis period.
- Reagents and consumables segment was the highest revenue-generating segment in 2016, and is expected to continue its dominance in future.
- North America dominated global polymerase chain reaction technologies market in 2016, and is projected to continue its dominance in future.
- China is expected to grow highest in the Asia-Pacific region during the forecast period.
- Services segment was the largest contributor among the products and services segments.
Summary: “Shoulder Arthroplasty Market” includes Market Size, Share, Trends, Growth, Demand, Supply, Application, production, capacity utilization, supply, Analysis and Forecast
Shoulder replacement or shoulder arthroplasty procedures are performed to replace the ball and sometimes the socket using a prosthesis made up of polythene and metal components. Several types of shoulder arthroplasties can be performed such as partial shoulder arthroplasty, total shoulder arthroplasty, and revision shoulder arthroplasty, depending on the severity of the shoulder joint damage.
Get Sample Copy of Report: https://www.alliedmarketresearch.com/request-sample/2599
Increase in incidence of arthritis and surge in in geriatric population drive the growth of the global shoulder arthroplasty market. In addition, rise in focus of manufacturers on developing advanced shoulder fracture repair devices supplements the market growth. However, increase in risk of postoperative injuries associated with shoulder arthroplasties hampers the market growth. Conversely, surge in investment by manufacturers to develop shoulder arthroplasty devices in the emerging economies and rise in initiatives to increase awareness towards available treatments for shoulder injuries are expected to provide profitable opportunities for market expansion.
The shoulder arthroplasty platform systems segment is expected to witness a growth rate of 8.4% from 2017 to 2023, owing to high investments by the key players in developing shoulder replacement platform systems such as GLOBAL UNITE Platform Shoulder System and Exactech shoulder system. The arthritis indication segment accounted for approximately half of the total market share in 2016, and is anticipated to continue its dominance throughout the forecast period. This is attributed to increase in incidence of various forms of arthritis such as osteoarthritis, rheumatoid arthritis, and other inflammatory arthritis.
The hospitals & clinics segment generated the highest revenue in 2016, accounting for two-thirds of the total market share, and is projected to maintain this trend throughout the forecast period. Moreover, outpatient surgical centers segment is expected to witness high growth rate of 9.0%, due to increase in number of shoulder arthroplasties being carried out in outpatient surgical facilities, as they are considered to be as safe as inpatient shoulder arthroplasty surgeries.
View Detail Summary of this report: https://www.alliedmarketresearch.com/shoulder-arthroplasty-market
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions”. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.